NovaBay Pharmaceuticals Inc (AMEX:NBY)
$ 0.7293 -0.0508 (-6.51%) Market Cap: 3.56 Mil Enterprise Value: 5.03 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

NovaBay Pharmaceuticals Inc at LD Micro Main Event Transcript

Oct 26, 2022 / 03:00PM GMT
Release Date Price: $130.22 (+11.89%)
Justin Hall
NovaBay Pharmaceuticals, Inc. - CEO

Here I am.

Unidentified Participant

Good morning.

Justin Hall
NovaBay Pharmaceuticals, Inc. - CEO

To our very large crew -- I think we can go through this relatively quickly and leave some time for Q&A towards the end.

Forward-looking statements again. Our corporate overview -- the way that I like to explain NovaBay is in three different verticals. The first vertical is in eyecare; the hero product is Avenova. The second vertical is for skincare. That is the DERMAdoctor brand. And the third vertical is in wound care, and that is the PhaseOne and NeutroPhase brands.

So one thing that all three of these verticals have in common is they are all problem-solving products. So nothing here is meant to be cosmetic. It is all scientifically developed and clinically creative.

Investment highlights. So the very first was just who we are -- $10 million trailing 12-month revenue. We plan to end the year with a stronger revenue projection. So maybe I will

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot